Literature DB >> 23402745

Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function.

Johannie Du Plessis1, Hanne Vanheel, Carl E I Janssen, Leonie Roos, Tomas Slavik, Paraskevi I Stivaktas, Martin Nieuwoudt, Stefan G van Wyk, Warren Vieira, Etheresia Pretorius, Mervyn Beukes, Ricard Farré, Jan Tack, Wim Laleman, Johan Fevery, Frederik Nevens, Tania Roskams, Schalk W Van der Merwe.   

Abstract

BACKGROUND & AIMS: Bacterial infections commonly occur in decompensated cirrhosis resulting from bacterial translocation from the intestine. We studied the role of intestinal macrophages and the epithelial barrier in cirrhosis.
METHODS: Forty-four patients with NASH/ASH cirrhosis (decompensated n=29, compensated n=15) and nineteen controls undergoing endoscopy were recruited. Serum was obtained and LPS and LBP levels determined. Intestinal macrophages were characterized by flow cytometry, immunohistochemistry, and nitric oxide (NO) production measured in supernatant of cultured duodenal samples. Quantitative RT-PCR was performed on duodenal biopsies assessing 84 inflammatory genes. Protein levels of cytokines/chemokines were assessed in serum and supernatant. The duodenal wall was assessed by electron microscopy, tight junction protein expression determined by RT-PCR, immunohistochemistry, and Western blot and, functional analysis performed by transepithelial resistance measurement and permeability studies.
RESULTS: Increased plasma LPS, LBP levels and higher numbers of duodenal CD33(+)/CD14(+)/Trem-1(+) macrophages, synthesizing iNOS and secreting NO were present in decompensated cirrhosis. Upregulation of IL-8, CCL2, CCL13 at the transcriptional level, and increased IL-8, and IL-6 were detected in supernatant and serum in cirrhosis. IL-6 and IL-8 co-localised with iNOS(+) and CD68(+), but not with CD11c(+) cells. Electron microscopy demonstrated an intact epithelial barrier. Increased Claudin-2 was detected by Western blot and immunohistochemistry, while decreased transepithelial resistance and increased duodenal permeability were detected in decompensated cirrhosis.
CONCLUSIONS: Our study shows the presence of activated CD14(+)Trem-1(+)iNOS(+) intestinal macrophages, releasing IL-6, NO, and increased intestinal permeability in patients with cirrhosis, suggesting that these cells may produce factors capable of enhancing permeability to bacterial products.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23402745     DOI: 10.1016/j.jhep.2013.01.038

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  53 in total

1.  Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

Authors:  Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos
Journal:  World J Hepatol       Date:  2015-08-18

2.  Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis.

Authors:  Jamie E Mells; Ping P Fu; Pradeep Kumar; Tekla Smith; Saul J Karpen; Frank A Anania
Journal:  J Nutr Biochem       Date:  2014-12-06       Impact factor: 6.048

3.  Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice.

Authors:  Peng Chen; Peter Stärkel; Jerrold R Turner; Samuel B Ho; Bernd Schnabl
Journal:  Hepatology       Date:  2015-01-30       Impact factor: 17.425

4.  Oral citrulline supplementation protects female mice from the development of non-alcoholic fatty liver disease (NAFLD).

Authors:  Cathrin Sellmann; Cheng Jun Jin; Anna Janina Engstler; Jean-Pascal De Bandt; Ina Bergheim
Journal:  Eur J Nutr       Date:  2016-08-05       Impact factor: 5.614

Review 5.  Altered Microbiome in Patients With Cirrhosis and Complications.

Authors:  Chathur Acharya; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2018-08-09       Impact factor: 11.382

Review 6.  Interactions between the intestinal microbiome and liver diseases.

Authors:  Bernd Schnabl; David A Brenner
Journal:  Gastroenterology       Date:  2014-01-15       Impact factor: 22.682

Review 7.  Gastrointestinal dysfunction in liver cirrhosis.

Authors:  Evangelos Kalaitzakis
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

8.  Hepatorenal Syndrome.

Authors:  Claire Francoz; François Durand; Jeffrey A Kahn; Yuri S Genyk; Mitra K Nadim
Journal:  Clin J Am Soc Nephrol       Date:  2019-04-17       Impact factor: 8.237

Review 9.  Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting.

Authors:  Arjuna Singanayagam; Evangelos Triantafyllou
Journal:  Front Immunol       Date:  2021-04-02       Impact factor: 7.561

Review 10.  Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.

Authors:  Sena Bluemel; Brandon Williams; Rob Knight; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-29       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.